secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001551152-23-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance
--------------------------------------------------------------------------------

- Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).
- Immunology portfolio $5.587B (-9%); Humira $3.541B (-25.2%), Skyrizi $1.360B (+44.7%), Rinvoq $686M (+47.5%).
- Hematologic oncology $1.416B (-14%); Imbruvica $878M (-25.2%), Venclexta $538M (+13.7%).
- Raises FY 2023 adj. diluted EPS guidance from $10.62-$11.02 to $10.72-$11.12.
- Neuroscience $1.695B (+13.9%); aesthetics $1.300B (-5.4%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/0001551152-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/abbv-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001551152-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer